Atagabalin(PD-0200,390) is a drug developed byPfizerand related togabapentin,which similarly binds to the α2δcalcium channels(1and2).[1]It was under development as a treatment forinsomnia,[2][3][4]but was discontinued following unsatisfactory trial results.

Atagabalin
Clinical data
ATC code
  • none
Identifiers
  • [(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC10H19NO2
Molar mass185.267g·mol−1
3D model (JSmol)
  • C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN
  • InChI=1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1checkY
  • Key:IUVMAUQEZFTTFB-YUMQZZPRSA-NcheckY
☒NcheckY(what is this?)(verify)

See also

edit

References

edit
  1. ^Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins".Bioorganic & Medicinal Chemistry Letters.20(2): 461–4.doi:10.1016/j.bmcl.2009.11.118.PMID20005103.
  2. ^Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009)."Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit".British Journal of Clinical Pharmacology.68(2): 174–80.doi:10.1111/j.1365-2125.2009.03444.x.PMC2767279.PMID19694735.
  3. ^Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011)."Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology".Brain Research.1401:1–9.doi:10.1016/j.brainres.2011.05.025.PMC3197737.PMID21664606.
  4. ^Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models".Pharmaceutical Research.28(10): 2610–27.doi:10.1007/s11095-011-0490-x.PMID21681607.S2CID22241527.